ClinicalTrials.gg
Not yet recruitingNCT07860554PluvEquityUpdated Oct 6, 2026

Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 interventional study of Biopsy Procedure and Biospecimen Collection in Metastatic Castration-Resistant Prostate Adenocarcinoma and Stage IVB Prostate Cancer AJCC v8, sponsored by Emory University. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms — 21 open to participants now, 31 under way, 2 of them phase 3. lutetium (¹⁷⁷Lu) vipivotide tetraxetan · Prostatic Neoplasms.

Planned enrollment
14th of 41
88 · median 49
Started
2026
with 5 others
Phase 2
18 of 41
12 open now
Primary completion
2027-12
later than 17 of 30 live
Registered
41st of 41
by date

Among the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, this one is the 14th largest by planned enrollment, is one of 6 that started in 2026, is one of 18 in phase 2, reaches primary completion later than 17 of the 30 other live ones, and was the 41st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

21 of the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About lutetium (¹⁷⁷Lu) vipivotide tetraxetan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This phase II trial tests how well Pluvicto works in treating African American patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has continued to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production (castration-resistant). Pluvicto is a targeted radioligand therapy. It works like a guided missile, combining tumor seeking molecules with a radioactive isotope. It circulates through the bloodstream, binds to a protein on prostate cancer cells called prostate specific membrane antigen, and destroys them using radiation. Pluvicto is approved by the Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. This trial may help researchers determine the safety and efficacy of Pluvicto specifically in African American patients with metastatic castration-resistant prostate cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To establish the clinical efficacy of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in African American (AA) men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on one androgen receptor pathway inhibitor (ARPI) and have not been treated with taxane chemotherapy for mCRPC.

SECONDARY OBJECTIVES:

I. To establish in AA men with mCRPC who have progressed on one androgen receptor (AR) pathway inhibitor and have not been treated with taxane chemotherapy for mCRPC the:

Ia. Safety and tolerability of Pluvicto; Ib. Overall survival following treatment with Pluvicto; Ic. Objective radiographic response rate to Pluvicto; Id. Prostate specific antigen (PSA) response rate to Pluvicto; Ie. Impact of Pluvicto on quality of life.

TERTIARY/EXPLORATORY OBJECTIVES:

I. Identify tumor genomic and transcriptional profiles that are associated with response to Pluvicto in AA men.

II. Identify circulating tumor deoxyribonucleic acid (DNA) molecular features that are associated with response to Pluvicto in AA men.

III. Evaluate the association of genetic ancestry with response to Pluvicto in AA men.

OUTLINE:

Patients receive Pluvicto intravenously (IV) on day 1 of each cycle. Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo prostate specific membrane antigen (PSMA) positron emission tomography (PET), computed tomography (CT), bone scan, single photon emission computed tomography (SPECT), collection of blood samples, and optional biopsy throughout the trial.

After completion of study treatment, patients are followed up every 3 months for up to 36 months.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have the ability to understand and sign an approved form (ICF) prior to participation in any study procedures
  • Participants must have the ability to understand and comply with all protocol requirements
  • Participants must have the ability to understand and comply with institutional radiation safety requirements
  • Participants must be ≥ 18 years of age
  • Participants must self-identify as being African-American
  • Participants must have an (ECOG) performance status of 0 to 1
  • Participants must have histological pathological, and/or cytological confirmation of adenocarcinoma of the prostate
  • Participants have PSMA-positive disease on PSMA scan
  • Participants must have a castrate level of serum/plasma testosterone (\< 50 ng/dL or \< 1.7 nmol/L)
  • Participants must have progressed only once on prior second generation androgen receptor-directed therapy (ARDT) (abiraterone, enzalutamide, darolutamide, or apalutamide)

    • First generation androgen receptor inhibitor therapy (e.g. bicalutamide) is allowed but not considered as prior ARDT therapy
    • Second generation ARDT must be the most recent therapy received
  • Participants must have progressive mCRPC. Documented progressive mCRPC will be based on at least 1 of the following criteria:

    • Serum/plasma PSA progression defined as 2 increases in PSA measured at least 1 week apart. The minimal start value is 2.0 ng/mL; 1.0 ng/mL is the minimal starting value if confirmed rise in PSA is the only indication of progression
    • Soft-tissue progression defined (Prostate Cancer Working Group Scher Prostate Cancer 2016 Oncology Response Criteria [PCWG3]-modified [RECIST] version [v]1.1 [Eisenhauer et al 2009, Scher et al 2016])
    • Progression of bone disease: two new lesions; only positivity on the bone scan defines disease to bone (PCWG3 criteria [Scher et al 2016])
  • Participants must have ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization
  • Participants must have recovered to ≤ grade 2 from all toxicities related to prior therapies (i.e. prior chemotherapy, radiation, etc.) except alopecia
  • (ANC) ≥ 1.5 x 10\^9/L
  • ≥ 100 x 10\^9/L
  • ≥ 9 g/dL
  • Total \< 2 x the institutional (ULN). For participants with known Gilbert's syndrome ≤ 3 x ULN is permitted
  • (ALT) or aspartate aminotransferase (AST) ≤ 3.0 x ULN OR ≤ 5.0 x ULN for participants with liver metastases
  • Estimate (eGFR) ≥ 50 mL/min/1.73m\^2 using the Modification of Diet in Renal Disease (MDRD) equation
  • Albumin ≥ 2.5 g/dL
  • Candidates for change in ARDT as assessed by the treating physician

    • Participants cannot have previously progressed nor had intolerable toxicity to both enzalutamide and abiraterone

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with any of the following within 6 months of enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation
  • Previous PSMA-targeted radioligand therapy is not allowed
  • Prior treatment with cytotoxic chemotherapy for castration resistant or castrate sensitive prostate cancer (e.g., taxanes, platinum, estramustine, vincristine, methotrexate, etc.), immunotherapy or biological therapy (including monoclonal antibodies). (Note: Taxane exposure [maximum 6 cycles] in the or neoadjuvant setting is allowed if 12 months have elapsed since completion of this adjuvant or neoadjuvant therapy. Prior treatment with sipuleucel-T is allowed)
  • Any agents within 28 days prior to day of randomization
  • Known to any of the study treatments or its or to drugs of similar classes
  • Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, biological therapy, or investigational therapy
  • Transfusion or use of bone marrow stimulating agents for the sole purpose of making a subject eligible for study inclusion
  • Participants with a history of central nervous system (CNS) who are neurologically unstable, symptomatic, or receiving for the purpose of maintaining neurologic integrity. Participants with are eligible if received therapy (surgery, radiotherapy, gamma knife), asymptomatic and neurologically stable without corticosteroids. Participants with epidural disease, canal disease and prior cord involvement are eligible if those areas have been treated, are stable, and not neurologically impaired
  • A superscan as seen in the baseline bone scan, defined as 99mTc bone scintigraphy pattern demonstrating diffuse, confluent, and intense radiotracer uptake throughout the majority of the axial and appendicular skeleton, with markedly reduced or absent renal visualization and minimal soft tissue activity
  • Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression
  • History or current diagnosis of the following electrocardiography () abnormalities indicating significant risk of safety for study participants:

    • Concomitant cardiac arrhythmias, e.g. sustained ventricular tachycardia, complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third degree AV block)
    • History of familial long syndrome or known family history of Torsades de Pointe
    • Cardiac or cardiac repolarization abnormality, including any of the following: history of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to starting study treatment
  • Concurrent serious (as determined by the principal investigator) medical conditions, including, but not limited to class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active or C or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation

    • -infected participants who are at a low risk of AIDS-related outcomes may participate in this trial
    • Participants with an active documented coronavirus disease 2019 (COVID-19) infection (any grade of disease severity) at time of may be included only when completely recovered (in accordance with local guidance)
  • Diagnosed with other that are expected to alter or may interfere with disease assessment. Participants with a prior history of malignancy that has been adequately treated and who have been disease free and treatment free for more than 3 years prior to randomization are eligible, as are participants with adequately treated non-melanoma skin cancer and superficial bladder cancer
  • Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 14 weeks after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above. If local regulations deviate from the methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF
  • Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: Participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (including [incl.] pads, drainage) are allowed
  • History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
  • Any condition that precludes raised arms position
  • Eligible for treatments other than ARDT based on presence of any mutations or biomarkers that are known as predictors of better response (e.g., AR-V7 or BRCA)
  • Not able to understand and to comply with study instructions and requirements
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Treatment (Pluvicto)

    Patients receive Pluvicto IV on day 1 of each cycle. Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET scan, CT scan, bone scan, collection of blood samples, and optional SPECT scans and pre- and post-treatment biopsies.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Bone Scan · Procedure: Computed Tomography · Drug: Lutetium Lu 177 Vipivotide Tetraxetan · Procedure: PSMA PET Scan · Other: Questionnaire Administration · Procedure: Single Photon Emission Computed Tomography

Interventions

  • ProcedureBiopsy Procedure

    Undergo biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureBone Scan

    Undergo bone scan

    Also known as: Bone Scintigraphy

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • DrugLutetium (¹⁷⁷Lu) vipivotide tetraxetanStudies of Lutetium (¹⁷⁷Lu) vipivotide tetraxetanLutetium (¹⁷⁷Lu) vipivotide tetraxetan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: 177Lu-labeled PSMA-617, 177Lu-PSMA-617, AAA 617, AAA-617, AAA617, Lu177-PSMA-617, Lutetium Lu 177-PSMA-617, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, Lutetium-177-PSMA-617, Pluvicto

  • ProcedurePSMA PET Scan

    Undergo PSMA PET scan

    Also known as: Prostate-specific Membrane Antigen PET, PSMA PET, PSMA-Positron emission tomography

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureSingle Photon Emission Computed Tomography

    Undergo SPECT

    Also known as: Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon

06

What researchers measure

Primary outcomes

  1. Radiographic progression-free survival (rPFS)

    Will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median rPFS will be estimated using the Brookmeyer-Crowley approach.

    Time frame: From the start of study treatment to the first objective documentation of radiographic disease progression or death, assessed up to 36 months

Secondary outcomes

  1. Incidence of adverse events

    Will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Frequencies and percentages will be used to summarize safety events. Toxicities will be tabulated by grade, association, and cycle number.

    Time frame: Up to 36 months

  2. Overall survival

    Will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median overall survival will be estimated using the Brookmeyer-Crowley approach.

    Time frame: From the start of study treatment to the date of death, assessed up to 36 months

  3. Objective response rate

    ORR is defined as the proportion of subjects achieving a best overall response of complete response (CR) or partial response (PR). Will be summarized with a 2-sided 95% confidence interval using the Clopper-Pearson method.

    Time frame: Up to 36 months

  4. Disease control rate (DCR)

    DCR is defined as the proportion of subjects achieving a best overall response of CR, PR, or stable disease.

    Time frame: Up to 36 months

  5. Prostate specific antigen (PSA) response rate

    Will be defined as the proportion of subjects achieving a ≥ 50% decline (PSA50) or ≥ 90% decline (PSA90) in PSA from baseline, confirmed per Prostate Cancer Working Group Scher Prostate Cancer 2016 Oncology Response criteria. PSA50 and PSA90 will be summarized with 2-sided 95% confidence intervals using the Clopper-Pearson method.

    Time frame: Up to 36 months

  6. Health related quality of life (FACT-P)

    Will be quantified through patient-reported outcome instruments administered during study participation using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Descriptive statistics such as mean, median, interquartile range, and min/max will be reported for continuous variables, and frequencies and percentages will be reported for categorical variables.

    Time frame: Up to 36 months

  7. Health related quality of life (FACT-RNT)

    Will be quantified through patient-reported outcome instruments administered during study participation using the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT). Descriptive statistics such as mean, median, interquartile range, and min/max will be reported for continuous variables, and frequencies and percentages will be reported for categorical variables.

    Time frame: Up to 36 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 13 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 6, 2026
StartEst.
Nov 2, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07860554
Lead sponsor
Emory University
Responsible party
Jacob Berchuck, MD (Principal Investigator, Emory University) — Principal investigator
First posted
Oct 6, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Wilena Session
Contact
wsessio@emory.edu
404-778-3448
Jacob E Berchuck, MD
principal investigator · Emory University Hospital/Winship Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium (¹⁷⁷Lu) vipivotide tetraxetan

Start the discussion